Abstract
Purpose of review: This review provides an overview of the hemangiopericytoma/solitary fibrous tumor (HPC/SFT) spectrum of tumors, focusing on the histopathologic characteristics, clinical features, diagnosis, and treatment of HPC/SFT. Recent findings: Due to the relatively insensitive nature of HPC/SFT to radiotherapy and cytotoxic chemotherapy, new therapies are needed for treatment of advanced disease. Inhibition of angiogenic pathways may provide a novel therapeutic mechanism for targeting this malignancy.combination therapy with temozolomide and bevacizumab has recently emerged as a potentially promising regimen for HPC/SFT. Summary: With many novel targeted therapies currently in development for soft tissue sarcomas, a better understanding of the molecular pathogenesis and aberrations of HPC/SFT is needed to determine optimal therapeutic agents. Identifying appropriate targets and designing rational prospective clinical trials will not only improve treatment of HPC/ SFT but will also lead to a new paradigm of personalized, targeted therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 327-331 |
Number of pages | 5 |
Journal | Current opinion in oncology |
Volume | 21 |
Issue number | 4 |
DOIs | |
State | Published - Jul 2009 |
Keywords
- Antiangiogenesis
- Hemangiopericytoma
- Solitary fibrous tumor
- Targeted therapy
- Vascular endothelial growth factor
ASJC Scopus subject areas
- Oncology
- Cancer Research